Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study
| Autor: | Adolfo Aita, Paolo Verdecchia, Lorenza Scotti, Andrea Di Lenarda, Fabio Ferrante, A. Iorio, Maria Gabriella Molini, Francesco Adamo, Vincenzo Russo, Giulia Benedetti, Corrado Lodigiani, Francesco Paciullo, Claudia Bartolini, Antonio D'Onofrio, EP Lanati, Carmine Mazzone, Francesco Fedele |
|---|---|
| Přispěvatelé: | Verdecchia, Paolo, D'Onofrio, Antonio, Russo, Vincenzo, Fedele, Francesco, Adamo, Francesco, Benedetti, Giulia, Ferrante, Fabio, Lodigiani, Corrado, Paciullo, Francesco, Aita, Adolfo, Bartolini, Claudia, Molini, Maria Gabriella, Di Lenarda, Andrea, Mazzone, Carmine, Scotti, Lorenza, Lanati, Elena Paola, Iorio, Arianna, Verdecchia, P, D'Onofrio, A, Russo, V, Fedele, F, Adamo, F, Benedetti, G, Ferrante, F, Lodigiani, C, Paciullo, F, Aita, A, Bartolini, C, Molini, M, Di Lenarda, A, Mazzone, C, Scotti, L, Lanati, E, Iorio, A |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Time Factors Administration Oral Pyridone Novel oral anticoagulant Retrospective Studie Risk Factors Medicine Cumulative incidence Apixaban Stroke Aged 80 and over Drug Substitution Incidence (epidemiology) Incidence Effectivene Atrial fibrillation General Medicine Middle Aged Treatment Outcome Italy Cohort Female Cardiology and Cardiovascular Medicine medicine.drug Human medicine.medical_specialty Time Factor Pyridones Hemorrhage Drug Administration Schedule Persistence Internal medicine Humans Aged Retrospective Studies business.industry Risk Factor Retrospective cohort study medicine.disease Administration oral aged aged 80 and over atrial fibrillation drug administration schedule drug substitution factor xa inhibitors female hemorrhage humans incidence italy male middle aged pyrazoles pyridones retrospective studies risk factors stroke time factors treatment outcome Discontinuation Pyrazole Pyrazoles business Factor Xa Inhibitor Factor Xa Inhibitors |
| Popis: | Aims Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K antagonist oral anticoagulants (NOACs) play an important role in the assessment of risks and benefits of these drugs. Our aim was to evaluate persistence on treatment, incidence of major bleeding and incidence of a composite endpoint of major events, including all-cause death, myocardial infarction, stroke and systemic thromboembolism, during treatment with apixaban in a cohort of patients with nonvalvular atrial fibrillation (NVAF). Methods In this multicentre retrospective observational study, we retrieved data from medical records of five Italian hospitals on patients with a diagnosis of NVAF who initiated apixaban between 1 January 2014 and 31 March 2016 and had a first subsequent visit at the same hospital. Results We studied 766 patients with mean age of 74.2 (standard deviation 11.1) years and median CHADS2 and CHA2DS2VASc scores of 2.0 and 4.0, respectively. Over a median follow-up period of 339 days, persistence on treatment was 83.5% [95% confidence interval (95% CI) 75.5-89.1%]. The rate of major bleeding (per 100 person-years) was 1.15 (95% CI 0.39-1.90 per 100 person-years), while the cumulative incidence was 4.4% (95% CI 1.6-12.0). The rate of major events was 1.97 (95% CI 1.08-2.86) per 100 patient-years, with a cumulative incidence over the entire follow-up period of 7.7% (95% CI 4.6-12.8). Conclusion In real-life conditions, NVAF patients treated with apixaban show rates of treatment discontinuation and major bleedings, which are comparable to those found in the ARISTOTLE pivotal study, thus supporting its external validity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|